By Dr David Reddy, Chief Executive Officer of the Medicines for Malaria Venture, and Dr Harald Nusser, Head of Novartis Social Business In the 1990s, treating children with malaria in Africa was a grueling experience. The parasite had become resistant to the most common antimalarial treatments, and death rates were climbing – fast. […]